Synovial Sarcoma Treatment Market - Global
Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018-2026
Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of
cancer and is more prevalent in teenagers and young adults. Synovial sarcoma is highly metastatic
and spreads to other places, in almost 50% of the cases and lungs are the common site for
metastasis to occur. The cause behind occurrence of synovial sarcoma have not yet been
established, however, it is found to be associated with abnormality in chromosome X and
chromosome 18 in tumor cells. Depending on the type of cells involved, it is classified into
Monophasic and Biphasic, and poorly differentiated synovial sarcoma. Diagnosis of the synovial
sarcoma involves imaging of the affected area, biopsy, genetic testing, and bone scans. Treatment of
the synovial sarcoma involves a few approaches ranging from medication to surgery depending on
the condition of the patient. For instance, surgery is considered if the tumor has clear margins and
can be removed alongside healthy tissue. If a surgery is not possible then chemotherapy is opted
which can kill cancerous as well as healthy cells. Generally used chemotherapy drugs include
ifofsamide, doxorubicin, and other drugs include dacarbazine, epirubicin, temozolomide, docetaxel,
and gemcitabine. Moreover, radiotherapy may also be used alongside chemotherapy or as a
standalone therapy. Some other therapies include angiogenesis inhibitors, which can prevent growth
of tumor, and biological therapies to boost patient’s immunity system to fight against cancer. The
treatment options highly depend on individual condition of the patients, as there is no standard
treatment for it.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1571
Synovial Sarcoma Treatment Market Drivers